Daridorexant Hydrochloride Tablets 25mg (Quviviq® / クービビック錠25mg)

JPY ¥7,400

Japanese Orexin Receptor Antagonist for Insomnia Treatment (Daridorexant Hydrochloride 25mg). Oral tablet for once-daily administration before bedtime. 100 tablets (10 tablets per PTP sheet x 10 sheets). Mfd. by Nxera Pharma Japan Co., Ltd., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥6,808
10 - 19 12% JPY ¥6,512
20 + 18% JPY ¥6,068
SKU: QUV-25-TAB Category:

Description

Product Overview / 商品概要

Daridorexant Hydrochloride Tablets 25mg (クービビック錠25mg)
Generic: Daridorexant Hydrochloride / ダリドレキサント塩酸塩
Therapeutic Category: Orexin Receptor Antagonist – Insomnia Treatment / オレキシン受容体拮抗薬-不眠症治療薬-
Manufactured by: Nxera Pharma Japan Co., Ltd. / ネクセラファーマジャパン株式会社

Composition & Specification / 組成・規格

Active Ingredient: Daridorexant Hydrochloride 27.02mg (equivalent to Daridorexant 25mg) per tablet / 1錠中 ダリドレキサント塩酸塩27.02mg(ダリドレキサントとして25mg)
Additives: D-Mannitol, Microcrystalline cellulose, Povidone, Croscarmellose sodium, Hydrated silicon dioxide, Magnesium stearate, Hypromellose, Glycerin, Talc, Titanium dioxide, Black iron oxide, Iron sesquioxide / D-マンニトール、結晶セルロース、ポビドン、クロスカルメロースナトリウム、含水二酸化ケイ素、ステアリン酸マグネシウム、ヒプロメロース、グリセリン、タルク、酸化チタン、黒酸化鉄、三二酸化鉄
Appearance: Film-coated tablet, light purple to purple, height: 7mm, thickness: 4mm, mass: 0.155g, identification code: obverse: 25, reverse: i
外観: フィルムコーティング錠、淡紫~紫色、高さ:7mm、厚さ:4mm、質量:0.155g、識別コード:表面:25、裏面:i

Indications / 効能効果

EN: Insomnia
JA: 不眠症

Dosage and Administration / 用法用量

EN: Usually, adults are administered 50mg once daily orally immediately before bedtime. The dose may be reduced to 25mg once daily depending on the patient’s condition.
JA: 通常、成人にはダリドレキサントとして1日1回50mgを就寝直前に経口投与する。なお、患者の状態に応じて1日1回25mgを投与することができる。

Contraindications / 禁忌

EN: Patients with a history of hypersensitivity to any component of this product; patients with severe hepatic impairment (Child-Pugh Class C); patients receiving itraconazole, clarithromycin, voriconazole, posaconazole, ritonavir-containing preparations, cobicistat-containing preparations, ceritinib, or ensitrelvir fumarate
JA: 本剤の成分に対し過敏症の既往歴のある患者、重度の肝機能障害(Child-Pugh分類C)のある患者、イトラコナゾール・クラリスロマイシン・ボリコナゾール・ポサコナゾール・リトナビル含有製剤・コビシスタット含有製剤・セリチニブ・エンシトレルビル フマル酸を投与中の患者

Regulatory Information / 規制情報

Approval No.: 30600AMX00253000
Sales Started: December 2024 / 2024年12月
Classification Code: 87119
Storage: Store at room temperature / 室温保存
Shelf Life: 3 years / 3年

Packaging / 包装

Main Package (for sale): 100 tablets (10 tablets per PTP sheet x 10 sheets) / 100錠(10錠PTP×10)
Other Available Packages (by special order): 100 tablets (10 tablets per PTP sheet x 10 sheets)

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Daridorexant Hydrochloride Tablets 25mg (Quviviq® / クービビック錠25mg)”

メールアドレスが公開されることはありません。 が付いている欄は必須項目です

Export from Japan — Daridorexant Hydrochloride Tablets 25mg (Quviviq®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.